Pregled bibliografske jedinice broj: 104087
Allogeneic Stem Cell Transplantation in Treatment of Aggressive Lymphomas: Case Series
Allogeneic Stem Cell Transplantation in Treatment of Aggressive Lymphomas: Case Series // Croatian medical journal, 43 (2002), 5; 565-568 (recenziran, članak, stručni)
CROSBI ID: 104087 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Allogeneic Stem Cell Transplantation in Treatment of Aggressive Lymphomas: Case Series
Autori
Labar, Boris ; Bogdanić, Vinko ; Nemet, Damir ; Mrsić, Mirando ; Serventi-Seiwerth, Ranka ; Sertić, Dubravka ; Golubić-Čepulić, Branka ; Vrtar, Mladen ; Šantek, Fedor ; Batinić, Drago ; Mikulić, Mirta ; Pulanić, Dražen
Izvornik
Croatian medical journal (0353-9504) 43
(2002), 5;
565-568
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, stručni
Ključne riječi
antineoplastic combined chemotherapy protocols; busulfan; carmustine; cyclophosphamide; cytarabine; etoposi-de;
Sažetak
Aim. To assess the outcome of allogeneic stem cell transplantation in patients with aggressive lymphoma. Methods. Between 1991 and 2002, 22 patients with aggressive lymphoma in advanced phase of the disease under-went allogeneic stem cell transplantation at the Division of Haematology, Zagreb University Hospital Center. Seventeen patients received stem cells from the bone marrow. Eighteen patients underwent total body irradiation and received cyclophosphamide for conditioning, whereas the rest of the patients received busulfan and cyclophosphamide (n=2) or chemotherapeutic protocol combining carmustine, melphalan, etoposide, and cytarabine (BEAM regimen)(n=2). All patients received cyclosporin and short methotrexate for the prophylaxis of graft-versus-host disease (GVHD).Results. Three months after allo-transplantation, 17 patients had complete remission, 3 patients had active disease, and the outcome in 2 patients was early death. Nine patients were alive and in complete remission for 4 to 124 months, whereas 13 patients died (8 because of disease progression and 3 because of GVHD and infection). The probability of overall survival at 4 years was 47%. Conclusion. Allogeneic transplantation is an effective therapy for advanced aggressive lymphoma. Because of high treatment-related toxicity and mortality, prospective trials are needed to asses the best time when to apply this treat-ment.
Izvorni jezik
Engleski
Znanstvena područja
Javno zdravstvo i zdravstvena zaštita
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb
Profili:
Mladen Vrtar
(autor)
Mirta Mikulić
(autor)
Fedor Šantek
(autor)
Mirando Mrsić
(autor)
Dubravka Sertić
(autor)
Drago Batinić
(autor)
Ranka Serventi-Seiwerth
(autor)
Boris Labar
(autor)
Dražen Pulanić
(autor)
Damir Nemet
(autor)
Vinko Bogdanić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
Uključenost u ostale bibliografske baze podataka::
- SCIexp